Key result
Dynamic blood cfDNA levels show potential for predicting stroke severity and outcomes.
Answers are grounded in this paper and cite their sources.
There is currently no proposed stroke biomarker with consistent application in clinical practice. A number of studies have examined cell-free DNA (cfDNA), which circulates in biological fluids during stroke, as a potential biomarker of this disease. The data available suggest that dynamically-determined levels of blood cfDNA may provide new prognostic information for assessment of stroke severity and outcome. However, such an approach has its own difficulties and limitations. This review covers the potential role of cfDNA as a biomarker in stroke, and includes evidence from both animal models and clinical studies, protocols used to analyze cfDNA, and hypotheses on the origin of cfDNA.
No takes yet. Share an insight, caveat, or question.
Glebova et al. (2018) conducted a review in Stroke. Cell-free DNA (cfDNA) was evaluated on Stroke severity and outcome assessment. Dynamically-determined blood cell-free DNA (cfDNA) levels may provide prognostic information for assessing stroke severity and outcome.
Synapse has enriched 10 related papers. Consider them for comparative context: